Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Forsteo Summary of Product Characteristics (SmPC)

Forsteo® (teriparatide): Use in Patients with Myeloma

Use of Forsteo in patients with multiple myeloma is not approved.

Detailed Information

Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide (contraindication).1

Osteoporosis or pathological fracture may be one of the first signs of multiple myeloma. Rapidly declining bone mineral density or low trauma pathological fracture may warrant further evaluation, including testing for monoclonal gammopathy.2

References

1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Faiman B, Licata AA. New tools for detecting occult monoclonal gammopathy, a cause of secondary osteoporosis. Cleve Clin J Med. 2010;77(4):273-278. https://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/issues/articles/media_12ffa61_273.pdf

Date of Last Review: March 03, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question